-
Miranda Lambert Leads North Texans with Seven Grammy Nominations for 2027
-
DiDi Advances Robotaxi Operations in China with New R2 Vehicle and Expanded Safety Infrastructure
-
Smart Car Seats Tested: Do Sensors and Apps Actually Improve Safety?
-
XPENG Launches Two New Models in UK; Pony.ai Robotaxi Enters Pilot
-
NexCore and MetLife Investment Management Launch $1.3 Billion Senior Living Co-Investment Venture
-
Galway Metals Intersects 1.8 g/t Gold Over 25.0 Metres and 0.7 g/t Gold Over 66.0 Metres at Clarence Stream
-
RuffleButts + RuggedButts Featured in Hasbro's 2026 Holiday Gift Guide
-
KIDZ AI Announces Strategic Collaboration with Synestria to Optimize AI Infrastructure Performance
-
Brightline Interactive and TruWeather Solutions Sign MOU to Bring Weather Data into SpatialCore Physical AI Platform
-
Avino Announces Key Technical Appointment
-
HippoFi Achieves OTCID Market Designation, Opening a New Chapter of Commercial Growth
-
Gabriel Resources Provides Corporate and Financing Update
-
MedMira Receives U.S. FDA Breakthrough Device Designation for Its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
-
Pivotree Announces Third Quarter 2026 Results
-
Ur-Energy Commences Baseline Study Fieldwork; Nears Completion of Technical Report at Lost Soldier Uranium Project, Wyoming
-
ImageWorks Display Advances Whole-Store Solutions with a Re-Imagined Planniq Strong and Planniq Chill
-
Razavi Law Group Partners with Chapman University to Prepare the Next Generation of Attorneys
-
Broad Clinical Labs Drives Strong Digital Engagement by Connecting Customers with Published Research Through Bioz
-
PRAAMS AI Co-Investor Now Covers 400,000+ Global Instruments, With Responses From 3 Seconds, Cost From US$0.01, and Scalability to Millions of Users
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 17
-
Driving Global Innovation - GTDC Summit APJ Underscores Distribution's Transformative Power
-
Pilot-Founded Solara Global Jet Offers Charter, Leases and Air Cargo Nationwide and Overseas
-
How to Turn Your Garage into Usable Living Space
-
Glidewell Opens Applications for 2027 Guiding Leaders Cohorts in California and North Carolina
-
The Next Healthcare Story Worth Telling May Be About Someone You Know
-
NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)
-
Atlas Signal Initiates Coverage of High Roller Technologies: ROLR(TM) Prediction-Markets Platform Goes Live on iPhone for U.S. Customers
-
Join Nord Precious Metals' Live Investor Webinar: Advancing Silver Production and High-Grade Exploration in Ontario
-
Executing Our Plan, Increasing Equity and Reducing Liabilities in Order to Build Long-Term Value
-
Dermata Highlights Additional Results and Photos from Cosmetic Study Evaluating Its Tome Foundational Treatment
-
Nexscient Reports Third Quarter 2026 Results; Revenue Rises Sequentially as Gross Margin Expands to Over 40%
-
Viking Global Technologies Announces Expansion of Grid Protection Technology Pilot with Another Major U.S. Electric Utility
-
TRNR Reports Record Q3 2026 Results, Driven by 66% Revenue Growth; M&A Pipeline Grows Significantly
-
Pinnacle Food Group Limited Achieves Laboratory-Scale Astaxanthin Extraction in Haematococcus pluvialis Program
-
FaZe Esports, a GameSquare Company, Wins Rainbow Six Championship at Osaka Major
-
Waste Energy to Host Shareholder Update Today at 4:30 PM EST; Management to Discuss WE #1 Commissioning, Revenue Opportunities and Growth Strategy
-
Klique Joins Lenovo AI Innovators, Bringing Its Enterprise AI Control Plane to Lenovo Hybrid AI Factory
-
Miami Allstars FC have Applied to Compete in the Women's Premier Soccer League, with the Club Targeting a 2027 or 2028 Debut in North Miami, Florida
-
Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
-
International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital
-
Tectonic Metals Completes Record Drill Program at Flat, Advances Five Pillars of Growth Toward Major 2027 Milestones
-
BioLargo Reports Third Quarter 2026 Results, Forecasting Commercial Breakout in 2027
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
Bluedrop Medical Appoints Mark Grant as CEO to Advance Commercialization and Strategic Growth
Medtech executive brings experience from early-stage ventures to global diabetes businesses, public company transformation and acquisitions
GALWAY, IRELAND / ACCESS Newswire / November 17, 2026 / Bluedrop Medical, a medical technology company developing a home-based clinical surveillance platform for the earlier identification of diabetic foot complications, today announced the appointment of Mark Grant as Chief Executive Officer. Grant will lead Bluedrop as it builds on its proprietary technology, clinical evidence and experienced team to advance commercial adoption and grow revenue.
Diabetic foot complications are a major cause of morbidity among people with diabetes and can lead to complex wound care, hospitalization and amputation. Bluedrop has developed an integrated approach to clinical surveillance that connects patients, data and care teams. Its OneStep Foot Scanner captures thermal and visual data from patients' feet at home, and AI-assisted analysis identifies changes that may warrant clinical attention, enabling more timely intervention and improved patient outcomes.
"Bluedrop has made important progress through sustained investment in technology, clinical development and the commitment of its people," said Paul Gilson, Chairman of Bluedrop Medical. "As we focus on clinical adoption and commercial execution, Mark brings a valuable combination of entrepreneurial leadership, experience running a large diabetes devices and services business, and public company transformation that complements our existing leadership team."
Grant has more than two decades of healthcare and medtech leadership experience, in businesses ranging from five-person, pre-revenue teams to a Medtronic diabetes devices and services business with more than $1.6 billion in annual revenue and 2,000 employees. During nearly two decades at Medtronic, his responsibilities spanned insulin delivery, continuous glucose sensing, digital engagement and patient support, along with reimbursement, payer access and care delivery experience directly relevant to Bluedrop's clinical and commercial pathway.
Most recently, as President and Chief Executive Officer of Nasdaq-listed Lifeward Ltd., Grant led strategic repositioning, operational change and capital formation across a portfolio including lower-body exoskeletons and AlterG Anti-Gravity systems, as well as the acquisition of technology for an AI-enabled upper-body robotic orthotic system. He previously held leadership roles at FLA Orthopedics and IMRA Surgical and positions at Bristol-Myers Squibb, and has served as a board member, strategic advisor and angel investor in healthcare businesses.
"What attracted me to Bluedrop was the significance of the clinical need, the work already accomplished and the depth of expertise across the organization," said Grant. "We have an opportunity to build more than a single device business: an evidence-based clinical surveillance platform that helps patients and care teams recognize important changes earlier. Our focus will be on clear priorities, disciplined execution and demonstrating the clinical and economic value needed to drive adoption and sustainable growth."
Bluedrop's institutional supporters include Atlantic Bridge, Elkstone, Furthr VC, the European Innovation Council Fund and Enterprise Ireland. The company has published peer-reviewed clinical research on its OneStep technology, continues to expand its clinical evidence base and has established a comprehensive intellectual property portfolio around its platform.
About Bluedrop Medical
Bluedrop Medical is a Galway, Ireland-based medical technology company developing clinical surveillance technology for people at risk of diabetic foot complications. Its OneStep platform combines home-based thermal and visual foot assessment with AI-assisted analysis to support earlier clinical intervention and better patient outcomes. Learn more at www.bluedropmedical.com.
Media and Investor Inquiries
Bluedrop Medical | Galway, Ireland | www.bluedropmedical.com | [email protected]
SOURCE: Bluedrop Medical
View the original press release on ACCESS Newswire
E.Rodriguez--AT